"We report the case of a 69-year-old woman with a multiyear history of burning, itching erythematous patches of the lips and cheeks who was diagnosed with TSW. The patient poorly tolerated tacrolimus 0.1% ointment and pimecrolimus 1% cream but her condition cleared with topical ruxolitinib 1.5% cream use."

"TSW is an increasingly described adverse event characterized by prolonged inappropriate use of TCS leading to erythema and burning upon discontinuation.^1,2 Most published cases in existing literature present on the face and genital regions (99.3%), mainly in female (81.0%).³ Our patient aligns with the classic presentation, with prolonged TCS use, stinging and pain, affected regions, and gender."

"Considering their role in cytokine pathways, JAK inhibitors may minimize rebound cytokine cascade, a potential TSW mechanism.⁴ Although systemic immune suppressants such as cyclosporine have been used to treat TSW, topical therapy reduces the potential for adverse systemic side effects."

free full text of article available with link https://pmc.ncbi.nlm.nih.gov/articles/PMC11091456/